| Shepherd Chiropractic Clinic S.c. | |
|
2343 Silvernail Rd Pewaukee WI 53072-5402 | |
| (262) 569-8050 | |
| Not Available |
| Full Name | Shepherd Chiropractic Clinic S.c. |
|---|---|
| Speciality | Clinic/Center |
| Location | 2343 Silvernail Rd, Pewaukee, Wisconsin |
| Authorized Official Name and Position | Dean S. Shepherd (PRESIDENT) |
| Authorized Official Contact | 2625698050 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Shepherd Chiropractic Clinic S.c. 2343 Silvernail Rd Pewaukee WI 53072-5402 Ph: (262) 569-8050 | Shepherd Chiropractic Clinic S.c. 2343 Silvernail Rd Pewaukee WI 53072-5402 Ph: (262) 569-8050 |
| NPI Number | 1295918555 |
|---|---|
| Provider Enumeration Date | 12/10/2007 |
| Last Update Date | 09/24/2014 |
| Medicare PECOS PAC ID | 7911080205 |
|---|---|
| Medicare Enrollment ID | O20080208000601 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
The government of Liberia, in partnership with the Center for Infection and Immunity (CII) at the Columbia University Mailman School of Public Health and EcoHealth Alliance, announced the discovery of Ebola virus in a bat in Liberia.
An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death among men and women worldwide.
Labopharm Inc. has announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA).
Gates Vascular Institute is now able to conduct safer exams using Spot Fluoroscopy, a cardiovascular X-ray dose management technology from Toshiba America Medical Systems, Inc. GVI utilizes Spot Fluoroscopy with its Infinix-i bi-plane to reduce radiation exposure to both patients and physicians.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295918555 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261Q00000X | Clinic/center | 2077 (Wisconsin) | Primary |
| Provider Name | Dean S Shepherd |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1992866305 PECOS PAC ID: 6002999398 Enrollment ID: I20080208000600 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
The government of Liberia, in partnership with the Center for Infection and Immunity (CII) at the Columbia University Mailman School of Public Health and EcoHealth Alliance, announced the discovery of Ebola virus in a bat in Liberia.
An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death among men and women worldwide.
Labopharm Inc. has announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA).
Gates Vascular Institute is now able to conduct safer exams using Spot Fluoroscopy, a cardiovascular X-ray dose management technology from Toshiba America Medical Systems, Inc. GVI utilizes Spot Fluoroscopy with its Infinix-i bi-plane to reduce radiation exposure to both patients and physicians.
› Verified 2 days ago
| Provider Name | Erin E Nash |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1104156140 PECOS PAC ID: 6800069691 Enrollment ID: I20111021000281 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
The government of Liberia, in partnership with the Center for Infection and Immunity (CII) at the Columbia University Mailman School of Public Health and EcoHealth Alliance, announced the discovery of Ebola virus in a bat in Liberia.
An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death among men and women worldwide.
Labopharm Inc. has announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA).
Gates Vascular Institute is now able to conduct safer exams using Spot Fluoroscopy, a cardiovascular X-ray dose management technology from Toshiba America Medical Systems, Inc. GVI utilizes Spot Fluoroscopy with its Infinix-i bi-plane to reduce radiation exposure to both patients and physicians.
› Verified 2 days ago
| Provider Name | Carly Rebecca Yaeger |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1245678689 PECOS PAC ID: 4981845344 Enrollment ID: I20130726000508 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
The government of Liberia, in partnership with the Center for Infection and Immunity (CII) at the Columbia University Mailman School of Public Health and EcoHealth Alliance, announced the discovery of Ebola virus in a bat in Liberia.
An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death among men and women worldwide.
Labopharm Inc. has announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA).
Gates Vascular Institute is now able to conduct safer exams using Spot Fluoroscopy, a cardiovascular X-ray dose management technology from Toshiba America Medical Systems, Inc. GVI utilizes Spot Fluoroscopy with its Infinix-i bi-plane to reduce radiation exposure to both patients and physicians.
› Verified 2 days ago
| Provider Name | Kayci M Timm |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1982016861 PECOS PAC ID: 7719101765 Enrollment ID: I20140612000765 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
The government of Liberia, in partnership with the Center for Infection and Immunity (CII) at the Columbia University Mailman School of Public Health and EcoHealth Alliance, announced the discovery of Ebola virus in a bat in Liberia.
An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death among men and women worldwide.
Labopharm Inc. has announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA).
Gates Vascular Institute is now able to conduct safer exams using Spot Fluoroscopy, a cardiovascular X-ray dose management technology from Toshiba America Medical Systems, Inc. GVI utilizes Spot Fluoroscopy with its Infinix-i bi-plane to reduce radiation exposure to both patients and physicians.
› Verified 2 days ago
| Provider Name | Grant Logan Johnson |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1346957198 PECOS PAC ID: 7113395880 Enrollment ID: I20221130002263 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
The government of Liberia, in partnership with the Center for Infection and Immunity (CII) at the Columbia University Mailman School of Public Health and EcoHealth Alliance, announced the discovery of Ebola virus in a bat in Liberia.
An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death among men and women worldwide.
Labopharm Inc. has announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA).
Gates Vascular Institute is now able to conduct safer exams using Spot Fluoroscopy, a cardiovascular X-ray dose management technology from Toshiba America Medical Systems, Inc. GVI utilizes Spot Fluoroscopy with its Infinix-i bi-plane to reduce radiation exposure to both patients and physicians.
› Verified 2 days ago
News Archive
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
The government of Liberia, in partnership with the Center for Infection and Immunity (CII) at the Columbia University Mailman School of Public Health and EcoHealth Alliance, announced the discovery of Ebola virus in a bat in Liberia.
An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death among men and women worldwide.
Labopharm Inc. has announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA).
Gates Vascular Institute is now able to conduct safer exams using Spot Fluoroscopy, a cardiovascular X-ray dose management technology from Toshiba America Medical Systems, Inc. GVI utilizes Spot Fluoroscopy with its Infinix-i bi-plane to reduce radiation exposure to both patients and physicians.
› Verified 2 days ago
Prohealth Medical Group Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 700 Quinlan Dr, Pewaukee, WI 53072 Phone: 262-695-5800 | |
Prohealth Care Medical Associates Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 800 Main Street, Room So173, Pewaukee, WI 53072 Phone: 262-695-1888 | |
The Ommani Center For Integrative Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1166 Quail Ct, Suite 210, Pewaukee, WI 53072 Phone: 262-695-5311 Fax: 262-695-9744 | |
Faithful Physician Services Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1109 Cecelia Drive, Pewaukee, WI 53072 Phone: 262-373-6733 Fax: 262-373-6018 | |
Rising Health Chiropractic Wellness Corp Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 601 Ryan St, Suite F, Pewaukee, WI 53072 Phone: 262-695-9698 Fax: 262-695-0144 | |
Prohealth Medical Group Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1279 Capitol Dr, Pewaukee, WI 53072 Phone: 262-928-9180 |